VISCHER advised Cytos Biotechnology Ltd (CYTN) in financing transaction that raised a total of CHF 24.3 million by selling 8.1 million shares at a price of CHF 3.00 per share. The rights offering was oversubscribed and share allocations included the use of authorized capital. The VISCHER team is led by Matthias Staehelin (Corporate) with Peter Kuehn and Dania Salvisberg.